Prostacyclin receptor desensitization is a reversible phenomenon in human platelets.
BACKGROUND
Long-term exposure of platelets to endogenous or exogenous prostacyclin or its analogues might result in desensitization of the platelet prostacyclin receptor in vitro and in vivo accompanied by a loss in receptor density on the platelet surface and a reduced sensitivity toward the inhibitory effects of prostacyclins. However, the reversibility of this process in platelets has not yet been investigated.


RESULTS
Human platelets desensitized by the chemically stable prostacyclin analogue iloprost showed a significant reduction in [3H]-iloprost binding sites that was reversed by saponin permeabilization. This indicates functionally active internalized prostacyclin receptors. To assess whether the internalized prostacyclin receptors recycle to the cell surface after withdrawal of the agonist, iloprost sensitivity and prostacyclin receptor binding properties of iloprost (30 nmol/L, 2 hours) desensitized platelets incubated in iloprost-free autologous plasma were investigated. While desensitized platelets showed a significant increase in IC50 for iloprost inhibition of thrombin-induced platelet aggregation, serotonin release, and p-selectin expression and a reduced iloprost-stimulated cAMP formation, platelet iloprost sensitivity was restored 3 hours after iloprost withdrawal. In addition, the significant reduction in Bmax and the increase in K(D) of prostacyclin receptors in desensitized platelets as revealed by [3H]-iloprost binding studies also returned to the initial values.


CONCLUSIONS
These results indicate that prostacyclin receptors internalized during short-term desensitization are not degraded but can be recycled rapidly to the platelet surface in a functionally active form after withdrawal of the agonist.
Fisch
A
A
Department of Medicine II, Johannes Gutenberg University, Mainz, Germany.
Tobusch
K
K
Veit
K
K
Meyer
J
J
Darius
H
H
D001792:Blood Platelets / Q000378:metabolism*; D002463:Cell Membrane Permeability; D000242:Cyclic AMP / Q000096:biosynthesis; D006801:Humans; D016285:Iloprost / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin / Q000097:blood* / Q000187:drug effects*; D012016:Reference Values
D010975:Platelet Aggregation Inhibitors; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin; D000242:Cyclic AMP; D016285:Iloprost